enVVeno Medical
NVNO | NASDAQ
$5.95
-$0.22 (-3.57%)
At close: Nov 16, 2026, 4:00 PM ET
$5.95
$0.00 (-0.08%)
After-hours:
Nov 16, 2026, 7:30 PM ET
enVVeno Medical Company Profile
Company profile explainedCompany Profile
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
Key Executives
| Name | Position |
|---|---|
| Robert A. Berman | Chief Executive Officer & Director |
| Hamed Alavi | Senior Vice President & Chief Technology Officer |
| Jennifer Bright | Chief Financial Officer |
| Avi Sharma | Senior Vice President of Clinical, Regulatory & Quality |
| Marc H. Glickman | Senior Vice President & Chief Medical Officer |
| Sandy Prietto | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | DEFA14A | Filing |
| Oct 29, 2026 | DEF 14A | Filing |
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Sep 15, 2026 | SC 13D/A | [Amend] Filing |
| Sep 14, 2026 | 4 | Filing |
| Aug 21, 2026 | S-3 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 14, 2026 | 8-K | Current Report |
| Jun 12, 2026 | 4 | Filing |
enVVeno Medical
| Country | United States |
| IPO Date | May 31, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Robert A. Berman |
Contact Details
70 Doppler Irvine,
California 92618 United States
Stock Details
| Ticker Symbol | NVNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661053 |
| CUSIP Number | 29415J205 |
| ISIN Number | US29415J2050 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove NVNO